ArticleMolecular therapy : the journal of the American Society of Gene Therapy2009
Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 48 citations in OpenAlex.
- Innate Immune-Cloaked Microgel-Coated Mesenchymal Stromal Cells Reverse Persistent Pulmonary Fibrosis via Reparative Macrophages.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Implant Renal Injury-Responsive Cells to Supplement Erythropoietin and Protect Kidney Injury.MedComm · 2025Article
- Chemical-Empowered Human Adipose-Derived Stem Cells with Lower Immunogenicity and Enhanced Pro-angiogenic Ability Promote Fast Tissue Regeneration.Stem cells translational medicine · 2022Article
- Cross-matching of allogeneic mesenchymal stromal cells eliminates recipient immune targeting.Stem cells translational medicine · 2021Article
- Microparticles derived from human erythropoietin mRNA-transfected mesenchymal stem cells inhibit epithelial-to-mesenchymal transition and ameliorate renal interstitial fibrosis.Stem cell research & therapy · 2020Article
- Genetic Engineering as a Strategy to Improve the Therapeutic Efficacy of Mesenchymal Stem/Stromal Cells in Regenerative Medicine.Frontiers in cell and developmental biology · 2020Review
- Biological Considerations in Scaling Up Therapeutic Cell Manufacturing.Frontiers in pharmacology · 2020Review
- Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour.International journal of molecular sciences · 2018Review
- Extracellular vesicles from bone marrow-derived mesenchymal stromal cells supportJournal of extracellular vesicles · 2018Article
- Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation.Stem cell reviews and reports · 2014Review
- Mesenchymal stem cells: immune evasive, not immune privileged.Nature biotechnology · 2014Review
- Nonviral gene delivery of erythropoietin by mesenchymal stromal cells.Gene therapy · 2012Article
- Non-hematopoietic stem cells as factories for in vivo therapeutic protein production.Gene therapy · 2012Review
- Organ specific regenerative markers in peri-organ adipose: kidney.Lipids in health and disease · 2011Article
- Insulin expressed from endogenously active glucose-responsive EGR1 promoter in bone marrow mesenchymal stromal cells as diabetes therapy.Gene therapy · 2010Article
- Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Autologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastases.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Casting doubt on the safety of "off-the-shelf" mesenchymal stem cells for cell therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine.Journal of cellular and molecular medicineReview
- Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autologous bone marrow mesenchymal stromal cells (MSCs) have been successfully used for the delivery of erythropoietin (EPO) in murine models of anemia and myocardial infarction. For clinical applications where a transient effect would be adequate, such as myocardial infarction, the use of EPO-engineered universal donor allogeneic MSCs would be a substantial convenience. We thus investigated whether MSCs from C57BL/6 mice would permit robust transient EPO delivery in normal BALB/c allorecipients. Implantation of MSCs overexpressing murine EPO led to increases in hematocrit in syngeneic and allogeneic mice, but the latter eventually developed severe anemia due to acquired neutralizing anti-EPO antibodies. As MSCs constitutively produce the CCL2 chemokine which may behave as an adjuvant to the anti-EPO immune response, experiments were performed using EPO-engineered MSCs derived from CCL2(-/-) mice and similar results were obtained. In conclusion, MHC-mismatched MSCs can break the tolerance to autoantigens and lead to the development of pathogenic autoantibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.